News & Media


Larner College of Medicine in the Media

The following news and stories about LCOM appeared in local and/or national media.


Bertges Clinical Trial Mentioned in Cardiovascular Business News

November 4, 2022 by Lucy Gardner Carson

(NOVEMBER 4, 2022) Professor of Surgery and UVMMC vascular surgeon Daniel J. Bertges, M.D., presented a clinical trial on paclitaxel drug-coated balloons (DCBs) at the VIVA Foundation’s VIVA22 conference in Las Vegas, according to CardiovascularBusiness.com.

Daniel J. Bertges, M.D.

(NOVEMBER 4, 2022) UVMMC vascular surgeon Daniel J. Bertges, M.D., professor of surgery, presented a late-breaking clinical trial on paclitaxel drug-coated balloons (DCBs) at the VIVA Foundation’s VIVA22 conference in Las Vegas, the news site CardiovascularBusiness.com reported in an article titled Drug-Coated Balloons an Effective Tool in the Battle Against Femoropopliteal Disease.” Results of the trial, which focused on Medtronic’s IN.PACT Admiral DCBs, indicated that DCBs are an effective option for the treatment of femoropopliteal artery disease and femoropopliteal in-stent restenosis.


Larner College of Medicine News

Recent news and stories from the college.

Bertges Clinical Trial Mentioned in Cardiovascular Business News

November 4, 2022 by Lucy Gardner Carson

(NOVEMBER 4, 2022) Professor of Surgery and UVMMC vascular surgeon Daniel J. Bertges, M.D., presented a clinical trial on paclitaxel drug-coated balloons (DCBs) at the VIVA Foundation’s VIVA22 conference in Las Vegas, according to CardiovascularBusiness.com.

Daniel J. Bertges, M.D.

(NOVEMBER 4, 2022) UVMMC vascular surgeon Daniel J. Bertges, M.D., professor of surgery, presented a late-breaking clinical trial on paclitaxel drug-coated balloons (DCBs) at the VIVA Foundation’s VIVA22 conference in Las Vegas, the news site CardiovascularBusiness.com reported in an article titled Drug-Coated Balloons an Effective Tool in the Battle Against Femoropopliteal Disease.” Results of the trial, which focused on Medtronic’s IN.PACT Admiral DCBs, indicated that DCBs are an effective option for the treatment of femoropopliteal artery disease and femoropopliteal in-stent restenosis.


Media Relations

To schedule an interview with a faculty member, student, or staff member at the UVM Larner College of Medicine:

Email Us
Call
: (802) 656-3111